Title of article :
A Rare Case of Pembrolizumab-Induced Reactivation ofHepatitis B
Author/Authors :
Boris, Avezbakiyev Department of Hematology and Oncology - Brookdale University Hospital - Medical Center - Brooklyn, USA , Pandey, Anita Department of Hematology and Oncology - Brookdale University Hospital - Medical Center - Brooklyn, USA , Ezemenari, Susan Department of Hematology and Oncology - Brookdale University Hospital - Medical Center - Brooklyn, USA , Liaukovich, Maksim Department of Hematology and Oncology - Brookdale University Hospital - Medical Center - Brooklyn, USA , Richard, Ivan Department of Hematology and Oncology - Brookdale University Hospital - Medical Center - Brooklyn, USA
Abstract :
Hepatitis B virus (HBV) infection is common across the world, especially in Asia, Africa, Southern Europe, and Latin America. Theassociation of HBV infection in patients suffering from different oncological conditions is well established. Many cases of HBVreactivation have been reported in patients on immunosuppressive chemotherapy and in patients undergoing hematopoieticbone marrow transplantations. Only one case has been reported so far of HBV reactivation in a patient treated withprogrammed cell death receptor 1 (PD-1) checkpoint inhibitors in the setting of HIV status. We report a case of a 51-year-oldmale, former smoker, diagnosed with stage IV poorly differentiated adenocarcinoma of the lung, and started on pembrolizumab,who developed reactivation of chronic hepatitis requiring antiviral therapy.
Keywords :
Pembrolizumab-Induced Reactivation , Hepatitis B , HIV , HBV
Journal title :
Case Reports in Oncological Medicine
